Handbook of Statistics in Clinical Oncology, Third Edition

Handbook of Statistics in Clinical Oncology, Third Edition

Paperback(3rd ed.)

$61.95

Overview

Many new challenges have arisen in the area of oncology clinical trials. New cancer therapies are often based on cytostatic or targeted agents, which pose new challenges in the design and analysis of all phases of trials. The literature on adaptive trial designs and early stopping has been exploding. Inclusion of high-dimensional data and imaging techniques have become common practice, and statistical methods on how to analyse such data have been refined in this area. A compilation of statistical topics relevant to these new advances in cancer research, this third edition of Handbook of Statistics in Clinical Oncology focuses on the design and analysis of oncology clinical trials and translational research.

Addressing the many challenges that have arisen since the publication of its predecessor, this third edition covers the newest developments involved in the design and analysis of cancer clinical trials, incorporating updates to all four parts:


  • Phase I trials: Updated recommendations regarding the standard 3 + 3 and continual reassessment approaches, along with new chapters on phase 0 trials and phase I trial design for targeted agents.
  • Phase II trials: Updates to current experience in single-arm and randomized phase II trial designs. New chapters include phase II designs with multiple strata and phase II/III designs.
  • Phase III trials: Many new chapters include interim analyses and early stopping considerations, phase III trial designs for targeted agents and for testing the ability of markers, adaptive trial designs, cure rate survival models, statistical methods of imaging, as well as a thorough review of software for the design and analysis of clinical trials.
  • Exploratory and high-dimensional data analyses: All chapters in this part have been thoroughly updated since the last edition. New chapters address methods for analyzing SNP data and for developing a score based on gene expression data. In addition, chapters on risk calculators and forensic bioinformatics have been added.

Accessible to statisticians and oncologists interested in clinical trial methodology, the book is a single-source collection of up-to-date statistical approaches to research in clinical oncology.

Product Details

ISBN-13: 9781138199491
Publisher: Taylor & Francis
Publication date: 05/16/2017
Edition description: 3rd ed.
Pages: 658
Product dimensions: 6.25(w) x 9.25(h) x (d)

About the Author

John J. Crowley is president and CEO of Cancer Research and Biostatistics (CRAB), Seattle, Washington, director of the SWOG Statistical Center, and a faculty member at the Fred Hutchinson Cancer Research Center. The author or coauthor of more than 350 refereed articles, book chapters, and other publications, Dr. Crowley is a fellow of the American Statistical Association and the American Association for the Advancement of Science and a member of the International Biometrics Society, the American Society for Clinical Oncology, and the International Association for the Study of Lung Cancer. He received his BA (1968) from Pomona College, Claremont, California, and his MS (1970) and PhD (1973) in biomathematics from the University of Washington, Seattle.

Antje Hoering, PhD, is a senior biostatistician at Cancer Research and Biostatistics (CRAB), Seattle, Washington. She is also an affiliate faculty member in the Department of Biostatistics at the University of Washington and an affiliate investigator at the Fred Hutchinson Cancer Research Center. Dr. Hoering is the lead statistician of the SWOG Myeloma Committee, the SWOG Early Therapeutics Subcommittee, and the Stand Up To Cancer, Pancreatic Dream Team. She is the coordinating statistician for the Myeloma Institute for Research and Therapy, the International Myeloma Committee, and the Pancreatic Cancer Research Team. She serves as a consultant on a variety of industry-sponsored studies and has been the biostatistics representative on two Type B meetings with the FDA. She is member of the American Statistical Association, the International Biometrics Society, and the International Myeloma Society. She received her BS (1985) from the University of Tubingen, Germany, her MS (1988) in physics from Oregon State University, Corvallis, and her PhD (1991) in physics from the Max Planck Institute for Theoretical Nuclear Physics, Heidelberg, Germany. She transitioned into biostatistics with a three-year NRSA postdoctoral fellowship with the Department of Biostatistics at the University of Washington and the Fred Hutchinson Cancer Research Center.

Table of Contents

Choosing a Phase I Design
Barry E. Storer
Dose Finding Designs Based on the Continual Reassessment Method
John O’Quigley and Alexia Iasonos
Pharmacokinetics in Clinical Oncology: Statistical Issues
Gary L. Rosner, Peter Müller, Simon Lunagomez, and Patrick A. Thompson
Statistics of Phase 0 Trials
Larry Rubinstein
CRM Trials for Assessing Toxicity and Efficacy
Sumithra Mandrekar and Dan Sargent
Seamless Phase I/II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents
Antje Hoering, Michael LeBlanc, and John J. Crowley
Overview of Phase II Clinical Trials
Stephanie Green
Designs Based on Toxicity and Response
Gina R. Petroni and Mark R. Conway
Designs Using Time to Event Endpoints/Single Arm versus Randomized Phase II Designs
Catherine M. Tangen and John J. Crowley
Phase II Selection Designs
P.Y. Liu, James (Jim) Moon, and Michael LeBlanc
Phase II with Multiple Subgroups: Designs Incorporating Disease Subtype or Genetic Heterogeneity
Michael LeBlanc, Cathryn Rankin, and John J. Crowley
Phase II/III Designs
Sally Hunsberger
On Use of Covariates in Randomization and Analysis of Clinical Trials
Garnet L. Anderson, Michael LeBlanc, P.Y. Liu, and John J. Crowley
Factorial Designs with Time to Event Endpoints
Stephanie Green
Early Stopping of Clinical Trials
Mary W. Redman
Noninferiority Trials
Kenneth J. Kopecky and Stephanie Green
Phase III Trials for Targeted Agents
Antje Hoering, Michael LeBlanc, and John J. Crowley
Adaptive Trial Designs
Brian P. Hobbs and J. Jack Lee
Design of a Clinical Trial for Testing the Ability of a Continuous Marker to Predict Therapy Benefit
William E. Barlow
Software for Design and Analysis of Clinical Trials
J. Jack Lee and Nan Chen
Cure-Rate Survival Models in Clinical Trials
Megan Othus, John J. Crowley, and Bart Barlogie
Design and Analysis of Quality of Life Data
Andrea B. Troxel and Carol M. Moinpour
Economic Analyses alongside Cancer Clinical Trials
Dean A. Regier and Scott D. Ramsey
Structural and Molecular Imaging in Cancer Therapy Clinical Trials
Brenda Kurland and David A. Mankoff
Prognostic Factor Studies
Martin Schumacher, Norbert Holländer, Guido Schwarzer, Harald Binder, and Willi Sauerbrei
Predictive Modeling of Gene Expression Data
Alexander Hapfelmeier, Waheed Babatunde Yahya, Robert Rosenberg, and Kurt Ulm
Explained Variation and Explained Randomness for Proportional Hazards Models
John O’Quigley and Ronghui Xu
Prognostic Groups by Tree-Based Partitioning and Data Refinement Methods
Michael LeBlanc and John J. Crowley
Risk Calculators
Donna Pauler Ankerst and Yuanyuan Liang
Developing a Score Based upon Gene Expression Profiling and Validation
Pingping Qu, John Shaughnessy, Bart Barlogie, and John J. Crowley
Analysis of DNA Microarrays
Shigeyuki Matsui and Hisashi Noma
Methods for SNP Regression Analysis in Clinical Studies:Selection, Shrinkage, and Logic
Michael LeBlanc, Bryan Goldman, and Charles Kooperberg
Forensic Bioinformatics
Keith A. Baggerly and Kevin R. Coombes
Index

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews